Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.

ABSTRACT: The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This decreases the cost of a vaccine and makes it affordable. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quic

SUBMITTER: Gupta T 

PROVIDER: S-EPMC7301105 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature